Markets ‘copy biologic’ Qiangke in China since 2011 Brenzys (Merck Canada) indications expanded to include plaque psoriasis, psoriatic arthritis and juvenile idiopathic arthritis. Brenzys approved in Australia in July 2016 and in Canada in August 2016. Samsung Bioepis (Biogen/Samsung)/ Merck, South Korea/USAīrenzys approved in South Korea in September 2015. Mycenax Biotech/TSH Biopharm Corp, TaiwanĬarrying out phase III trials in Japan and South Koreaįollow-on biological product' marketed in VietnamĪpproved by FDA in August 2016, by EC in June 2017, in Canada in August 2017 and in Australia in November 2017 Momenta was collaborating with Baxter on six biosimilars. LG Life Sciences (LG Chem)/ Mochida Pharmaceutical, South Korea/JapanĪpproved in Japan in January 2018 and in South Korea in March 2018 ‘Similar biologic’ launched in India in March 2015 Markets 'copy biological' AnBaiNuo in China since 2015 Positive phase III results reported in June 2016.ĭavictrel approved by South Korean MFDS on 11 November 2014 Global phase III trials in psoriasis and rheumatoid arthritis expected to be completed in July and October 2015. 'Similar biologic' launched in India in April 2013 Ĭoherus BioSciences/Baxalta (part of Shire), USA Table 1: Biosimilars and non-originator biologicals* of etanercept approved or in development Some of the etanercept biosimilars and non-originator biologicals* approved or in development are presented in Table 1. The patents on Enbrel will expire in the US in November 2028, after Amgen was granted a new patent, and expired in Europe in August 2015. Enbrel had sales of US$8.87 billion in 2015, before the advent of biosimilars, making it one of the top selling biologicals and a lucrative target for biosimilars developers, see Table 1. In addition to these precautions, you may also note that Intacept is safe while driving, and is is addictive in nature.The originator product, Amgen/Pfizer’s Enbrel (etanercept), was approved by the US Food and Drug Administration (FDA) in November 1998 and by the European Medicines Agency (EMA) in February 2000. A complete list of these interactions is given below. Other contraindications of Intacept have been discussed in the sections ahead.ĭrug interactions for Intacept have been reported in the medical literature. Infections are examples of such conditions. Intacept is not recommended if you suffer from certain medical conditions as it can have adverse effects. Further, the section on Intacept related warnings talks about Intacept's effects on the liver, heart and kidney. In addition, Intacept's effect is Severe during pregnancy and Severe for lactating mothers. Consult your doctor if these side effects become worse or stay for a longer duration. These side effects of Intacept are usually temporary and subside with the completion of treatment. Some other side effects of Intacept have been listed ahead. The side effects typically associated with Intacept include Nausea or vomiting, Cough, Headache. This information has been provided in detail in the dosage section. Individual symptoms and route of administration also determines the right dosage. The right dosage of Intacept depends on the age, gender, and medical history of the patient. Intacept also has some secondary and off-label uses. Rheumatoid Arthritis are some of its major therapeutic uses. Intacept is a commercial drug that is prescribed in the form of Injection.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |